Dr. Slaoui led the government’s vaccine development initiative and previously said he planned on stepping down once two COVID-19 vaccines and two therapies were available. CNBC reports that last week, Dr. Slaoui said he “decided to extend that in order to ensure that the operation continues to perform the way it has performed through the transition of administration,” adding “we’re getting close to the point where my value add is more limited.”
His role, ending by Feb. 12, is expected to start diminishing after the inauguration Jan. 20, a source who spoke on the condition of anonymity told CNBC.
Since two vaccines have already been authorized in the U.S., it’s unclear whether President-elect Biden’s team will appoint a scientific lead focused on vaccine development.
To view the full CNBC story, click here.
More articles on leadership and management:
FDA deputy commissioner to step down
4 leadership changes CEOs made during the pandemic
AHA writes letter urging HHS to expedite vaccination process
At Becker's 4th Annual CEO + CFO Roundtable, taking place November 2–5 in Chicago, more than 1,500 hospital and health system executives tackle decisions that determine whether organizations thrive or merely survive: protecting margins under cost pressure, choosing where to grow, renegotiating payer relationships, stabilizing the workforce and proving real ROI on technology. This is where leaders work through them together, face-to-face. Apply for complimentary registration now.
